论文部分内容阅读
目的观察应用苦参素联合乙型肝炎免疫球蛋白治疗慢性乙型肝炎的疗效。方法选择2006年1月～2006年9月住院的74例慢性乙型肝炎患者,随机分为两组。两组患者均采用常规治疗,治疗组加用乙型肝炎免疫球蛋白200U肌注每周1次,3个月为1个疗程;苦参素300mg,po,tid,疗程3个月。结果治疗组ALT复常率为81.6%(31/38),对照组为50.0%(18/36),两组差异有统计学意义(P<0.01)。治疗组TBIL复常率52.6%(20/38),对照组为25.0%(8/36),两组差异有统计学意义(P<0.01)。HBV-M、HBV-DNA的变化、肝纤维化指标前后差异亦有显著性。结论慢性乙型肝炎免疫清除期,乙型肝炎免疫球蛋白联合苦参素治疗中重度乙型肝炎可取得较好疗效,且不良反应较少。但尚有待更多病例验证。
Objective To observe the effect of oxymatrine combined with hepatitis B immunoglobulin in the treatment of chronic hepatitis B. Methods 74 patients with chronic hepatitis B who were hospitalized from January 2006 to September 2006 were randomly divided into two groups. The two groups of patients were treated with routine treatment, the treatment group plus Hepatitis B immunoglobulin 200U intramuscular injection once a week, 3 months for a course of treatment; Oxymatrine 300mg, po, tid, course of 3 months. Results The recovery rate of ALT was 81.6% (31/38) in the treatment group and 50.0% (18/36) in the control group, with significant difference between the two groups (P <0.01). The recovery rate of TBIL was 52.6% (20/38) in the treatment group and 25.0% (8/36) in the control group, with significant difference between the two groups (P <0.01). HBV-M, HBV-DNA changes, liver fibrosis indicators before and after the difference is also significant. Conclusions During the immune clearance of chronic hepatitis B, hepatitis B immunoglobulin combined with oxymatrine can be used to treat moderate-severe hepatitis B with better curative effect and fewer adverse reactions. But still more case validation.